FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
TOKYO and CAMBRIDGE, Mass., Jan 26, 2026 – (JCN Newswire via SeaPRwire.com) –&…
อ่านเพิ่มเติม